Avid Bioservices (NASDAQ:CDMO) reported Q3 EPS of $0.01, $0.02 better than the analyst estimate of ($0.01). Revenue for the quarter came in at $38 million versus the consensus estimate of $36.32 million.
GUIDANCE:
Avid Bioservices sees FY2023 revenue of $145-150 million, versus the consensus of $146 million.